UK-based AstraZeneca and Eli Lilly have signed an agreement to co-develop a new antibody selective for amyloid-beta 42 (Aβ42) for Alzheimer’s disease (AD) treatment, known as MEDI1814.
At present, Aβ42 is in Phase I trials as a potential disease-modifying treatment for AD.
The latest agreement builds on the existing collaboration between the companies related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.
AstraZeneca IMED Biotech Unit and business development executive vice-president Mene Pangalos said: “We are excited to build on an already productive collaboration with Lilly, which combines the expertise of our two companies, with a new programme focused on the amyloid beta pathway.
“MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a distinct approach to treating Alzheimer’s disease.”
One of the characteristics of AD is forming of plaques in the brain containing the peptide amyloid-beta (Aβ).
The new MEDI1814 binds selectively to Aβ42, a form of Aβ associated with the disease, in specific and dose-dependent reduction levels of this peptide, slowing the progression of AD.
Lilly Research Laboratories science and technology executive vice-president Jan Lundberg said: “At Lilly, we recognise the significant burden Alzheimer’s disease places on patients, caregivers and our society and we remain committed to finding ways to change the course of the disease.
“AstraZeneca brings capabilities and expertise and most importantly shares our passion to bring new medicines to patients suffering from this debilitating illness.”
